New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For SNY;BMY;MRK;JNJ;NVS;ABT;CELG;PFE;SHPG;GSK From The Last 14 Days
Check below for free stories on SNY;BMY;MRK;JNJ;NVS;ABT;CELG;PFE;SHPG;GSK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>
July 14, 2014
06:31 EDTABTAbbott to sell developed markets generics pharmaceuticals business to Mylan
Subscribe for More Information
06:17 EDTGSKXinhua: China indicts two GSK foreign investigators, The Guardian reports
Prosecutors in China have indicted two foreign investigators, British national Peter Humphrey and his wife, Yu Yingzeng, linked to GlaxoSmithKline, for illegally obtaining private information on Chinese citizens, reports The Guardian. Citing state media news agency Xinhua, the case is the first indictment by Chinese prosecutors against foreigners for illegal investigation. Reference Link
06:03 EDTSHPGStocks with implied volatility below IV index mean; BBBY SHPG
Subscribe for More Information
05:27 EDTSHPGShire receives revised proposal from AbbVie of GPB 53.20 per share
Subscribe for More Information
July 13, 2014
20:22 EDTABTMylan near buying Europe-based drug portfolio from Abbott, Reuters says
Subscribe for More Information
17:10 EDTSHPGShire said to seek bid of near 53 pounds per share from AbbVie, Reuters says
Subscribe for More Information
July 11, 2014
16:46 EDTSHPGStocks end week lower on European, Fed concerns
Subscribe for More Information
14:13 EDTSHPGShire, AbbVie didn't commit to further talks, Dow reports
Subscribe for More Information
13:58 EDTSHPGShire confirms meeting with AbbVie representatives
Subscribe for More Information
11:54 EDTSHPGAbbVie, Shire in active takeover talks, Bloomberg reports
AbbVie (ABBV) and Shire (SHPG) are in active talks about a potential merger after AbbVie raised its takeover offer for a fourth time, Bloomberg reports, citing people with knowledge of the matter. The talks are in the early stage and may not lead to an agreement, sources told Bloomberg. Shares of Shire are up 5%, or $12.04, to $250.65 following the report.
11:34 EDTSHPGShire jumps 5% after Bloomberg report on talks with AbbVie
11:33 EDTSHPGShire, AbbVie held talks after latest raised takeover offer, Bloomberg says
Subscribe for More Information
07:36 EDTJNJJohnson & Johnson Q2 EPS likely to exceed expectations, says Bernstein
Subscribe for More Information
July 10, 2014
16:12 EDTMRKMedivation names Dawn Svoronos as Chief Commercial Officer
Medivation (MDVN) announced Dawn Svoronos has been appointed as its chief commercial officer, reporting to David Hung, M.D., founder, CEO and president of Medivation. Svoronos currently is a member of Medivation's Board of Directors and is a former president of Europe and Canada for Merck & Co. (MRK), where she oversaw commercial operations in approximately 30 EU and EU accession countries. Svoronos will lead Medivation's commercial organization on an interim basis and will participate in the company's search for a permanent chief commercial officer. Cheryl Cohen, Medivation's former chief commercial officer, has left the company to pursue other opportunities.
15:55 EDTABTJoint venture with Fonterra a 'smart move' for Abbott, says Wells Fargo
Subscribe for More Information
15:43 EDTNVSNovartis siponimod designated as orphan treatment of dermatomyositis
Subscribe for More Information
14:01 EDTABTAbbott and Fonterra to form strategic alliance for dairy farming in China
Subscribe for More Information
12:43 EDTBMYBristol-Myers announces plans for Q3 submission of Opdivo BLA
Bristol-Myers Squibb announced earlier that, following discussions with the FDA, the company is planning a Q3 submission of a Biologics Licensing Application for Opdivo for previously treated advanced melanoma. This will mark the second tumor type for which Bristol-Myers Squibb has a regulatory submission underway for Opdivo in the U.S. “We continue to collaborate closely with the FDA on Opdivo and the planned submission in advanced melanoma represents an important step forward in our company’s commitment to deliver innovative treatment options for patients with cancer,” said Michael Giordano, MD, Head of Oncology Development, Bristol-Myers Squibb. The advanced melanoma BLA is based on data from Checkmate -037, a multinational, multicenter, randomized open-label Phase 3 trial evaluating Opdivo compared to dacarbazine or carboplatin/paclitaxel in patients with unresectable or metastatic melanoma who have been previously treated with Yervoy and, if BRAF-mutation positive, a BRAF inhibitor regimen. Bristol-Myers Squibb has proposed the name Opdivo, which, if approved by health authorities, will serve as the trade name for nivolumab.
09:40 EDTSHPGAbbVie, Shire not holding talks at this point as deadline approaches, CNBC says
AbbVie (ABBV) and Shire (SHPG) are not holding talks at this point, according to CNBC's David Faber, citing sources. Shire confirmed two days ago that it has received AbbVie's latest, raised takeover offer and that its board will meet to consider the proposal.
08:10 EDTABTMorgan Stanley's Vintage Values 2015 list selected
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use